BOSTON , Dec. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences... Read More

Financial release accessible online BOSTON , Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024 , are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7,... Read More

BOSTON , Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024 . The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024 . The call can be accessed via teleconference at: Q2 2025 Haemonetics... Read More

BOSTON , Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP ® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE ® portfolio of vascular closure... Read More

Financial release accessible online BOSTON , Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024 , are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2024.... Read More

BOSTON , July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced CE Mark certification and the first commercial European procedures for the SavvyWire ® Pre-Shaped Pressure Guidewire. The SavvyWire guidewire is the world's first and only sensor-guided 3-in-1 solution for... Read More

BOSTON , July 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, August 8, 2024 . The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 8, 2024 . The call can be accessed via teleconference at: Q1 2025 Haemonetics... Read More

BOSTON , June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP ® XL mid-bore venous closure device. The VASCADE MVP XL system expands Haemonetics' VASCADE ® portfolio of vascular closure systems featuring an innovative collapsible disc... Read More

BOSTON , May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was... Read More

BOSTON , May 21, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").... Read More

Financial release accessible online BOSTON , May 9, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024 , are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 9, 2024.... Read More

BOSTON , April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday , May 9, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 9, 2024 . The call can be accessed via teleconference at: Q4 2024 Haemonetics... Read More

BOSTON , April 4, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG ® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s... Read More

BOSTON , April 1, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of privately-held Chicago -based Attune Medical, the manufacturer of the ensoETM ® proactive esophageal cooling device. EnsoETM is the only FDA-cleared temperature regulation... Read More

BOSTON , March 5, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical products and solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to acquire privately-held Chicago -based Attune Medical, the manufacturer of the ensoETM ® proactive esophageal cooling device, the only FDA-cleared... Read More

BOSTON , Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon , President and CEO, will participate in a fireside chat with investors at the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5, 2024 at 7:30 a.m. ET . The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link:... Read More

BOSTON , Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon , President and CEO, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 8:45 a.m. ET . The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link:... Read More

Financial release accessible online BOSTON , Feb. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2024, which ended December 30, 2023 , are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 8,... Read More

BOSTON , Jan. 11, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, February 8, 2024 . The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 8, 2024 . The call can be accessed via teleconference at: Q3 2024 Haemonetics... Read More

BOSTON , Dec. 12, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of OpSens Inc., a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology. Haemonetics acquired all outstanding shares... Read More

BOSTON , Dec. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon , President and CEO, will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 9:45am Pacific time . The public may access Mr. Simon's presentation here . The live webcast can also be accessed under the Events & Presentations section of the Company's Investor Relations... Read More

All amounts in this press release are in Canadian dollars. QUÉBEC CITY , Nov. 2, 2023 /CNW/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF) announces that the Québec Superior Court (the "Court") issued an interim order (the "Interim Order") on October 31, 2023 in connection with the previously announced acquisition by Haemonetics Corporation ("Haemonetics") (NYSE: HAE), a global healthcare company,... Read More

BOSTON , Nov. 2, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2024, which ended September 30, 2023 , are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 2, 2023 . The conference call and... Read More

All amounts in this press release are in Canadian dollars QUÉBEC CITY, QC , Oct. 10, 2023 /CNW/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") with Haemonetics Corporation... Read More

Expands Haemonetics' Hospital portfolio with innovative fiber optic sensor technology for interventional cardiology Significant commercial synergies with Haemonetics' existing Vascular Closure portfolio Accelerates Haemonetics' transformational growth BOSTON , Oct. 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive... Read More

BOSTON , Oct. 5, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, November 2, 2023 . The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 2, 2023 . The call can be accessed via teleconference at: Q2 2024 Haemonetics... Read More

BOSTON , Aug. 29, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has announced that for the first time, patients have been treated with the company`s VASCADE MVP ® Venous Vascular Closure system in Germany . This marks the first use of the VASCADE system portfolio, widely used in U.S. hospitals,... Read More

Financial release accessible online BOSTON , Aug. 8, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal 2024, which ended July 1, 2023 , are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2023 . The... Read More

BOSTON , Aug. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has announced the election of Diane M. Bryant to its Board of Directors. Bryant recently served as Chairman and Chief Executive Officer of NovaSignal Corp., a medical technology and data company specializing in the assessment and... Read More

In the news release, Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2024 Results: August 8, 2023 , issued 10-Jul-2023 by Haemonetics Corporation over PR Newswire, we are advised by the company that in the third paragraph there was an incorrect link to the webcast. The complete, corrected release follows: BOSTON , July 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company... Read More

BOSTON , July 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2024 financial results at 6:00 am ET on Tuesday, August 8, 2023 . The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 8, 2023 . The call can be accessed via teleconference at: Q1 2024 Haemonetics... Read More

BOSTON , June 22, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for advancements to its NexSys PCS® plasma collection system. These include a new plasma collection bowl, featuring a patented design that optimizes... Read More

Financial release accessible online BOSTON , May 11, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2023, which ended April 1, 2023 , are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 11, 2023 . The... Read More

BOSTON , April 25, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2023 financial results at 6:00 am ET on Thursday, May 11, 2023 . The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 11, 2023 . The call can be accessed via teleconference at: Q4 2023 Haemonetics... Read More

BOSTON , April 20, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the release of its 2022 Corporate Responsibility Report. The report outlines key environmental, social and governance (ESG) initiatives of Haemonetics that align with its core values and corporate strategy. Haemonetics'... Read More

BOSTON , March 2, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on the next-generation software for the Cell Saver ® Elite ® + Autotransfusion System, with full market release available now. This software... Read More

BOSTON , Feb. 27, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon , President and CEO, will participate in a fireside chat with investors at the Raymond James 44th Annual Institutional Investors Conference on Monday, March 6, 2023 , at 8:40 a.m. ET . The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at:... Read More

BOSTON , Jan. 6, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2023 financial results at 6:00 am ET on Tuesday, February 7, 2023 . The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 7, 2023 . The call can be accessed via teleconference at: Q3 2023 Haemonetics... Read More

BOSTON , Dec. 19, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon , President and CEO, will present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023 at 2:15pm Pacific time . The public may access Mr. Simon's presentation live via audio webcast at: Click Here The live webcast can also be accessed under the Events & Presentations section of... Read More